PAMELA LOTT: Open Payments
NPI 1578640959 · COLUMBUS, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,108 in 115 payments from 15 companies in 2025. Trend: 2023 $1,300 · 2024 $2,017 · 2025 $2,108
Food & beverage: $2,009Education: $99
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 18 | $393 |
| ABBVIE INC. | 25 | $295 |
| Madrigal Pharmaceuticals | 16 | $294 |
| GENZYME CORPORATION | 11 | $245 |
| Aimmune Therapeutics, Inc. | 12 | $200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $192 |
| QOL Medical, LLC | 6 | $146 |
| Ardelyx, Inc. | 4 | $102 |
| Lilly USA, LLC | 4 | $62 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
Products named: TREMFYA, DUPIXENT, REZDIFFRA, ZENPEP, ENTYVIO, RINVOQ, Sucraid, IBSRELA.
Industry payments across MS — which companies pay providers there.
